Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
暂无分享,去创建一个
I. Pavord | A. Woodcock | P. Howarth | S. Johnston | S. Walker | D. Shaw | S. Fowler | I. Adcock | K. Chung | R. Djukanović | B. Hargadon | C. Brightling | R. Chaudhuri | J. Lordan | D. Robinson | P. Bradding | J. Busby | L. Heaney | C. Corrigan | J. Matthews | T. Harrison | C. Holweg | M. Bellamy | A. Menzies-Gow | G. Davies | R. Costello | J. Arron | Freda Yang | C. Borg | D. Jackson | M. Bourne | A. Mansur | D. Choy | R. Niven | C. Hanratty | V. Hudson | T. Hardman | Paula McCourt | Sarah E. Davies | D. Cowan | Joel Solis | Ian M Adnam Mary Catherine Michelle Clare Richard W Ch Adcock Azim Bellamy Borg Bourne Connolly Cost | Adnam Azim | C. Connolly | Gabrielle Gainsborough | T. Grandison | Avril Horn | G. Jones | María Nuñez | Katherine Smith | Roisin Stone | F. Yang | R. Stone | A. Azim | Geraldine Jones | K. Chung
[1] I. Pavord,et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.
[2] L. Heaney,et al. Different endotypes and phenotypes drive the heterogeneity in severe asthma , 2020, Allergy.
[3] D. Price,et al. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management , 2020, American journal of respiratory and critical care medicine.
[4] R. Chaudhuri,et al. Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study , 2019, Thorax.
[5] M. Humbert,et al. Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus , 2018, ERJ Open Research.
[6] G. Canonica,et al. Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. , 2018, Journal of Allergy and Clinical Immunology: In Practice.
[7] I. Pavord,et al. A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial , 2018, Trials.
[8] Richard Beasley,et al. After asthma: redefining airways diseases , 2017, The Lancet.
[9] C. Jenkins,et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[10] D. Price,et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry , 2016, Thorax.
[11] I. Pavord,et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK) , 2015, Thorax.
[12] E. R. Sutherland,et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.
[13] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[14] A. Chang,et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) , 2010, Thorax.
[15] Barmak Modrek,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.
[16] Mike Thomas,et al. Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.
[17] L. Boulet,et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.
[18] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.
[19] I. Pavord,et al. Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.